Product Description
IKKβ (Inhibitor of nuclear factor kappa-B kinase subunit beta), also known as IKK2, is a member of the serine/threonine protein kinase family (IκB kinase subfamily) that plays a pivotal role in the canonical NF-κB signaling pathway, innate immunity, and inflammatory responses. IKKβ is activated by various stimuli including TNFα, IL-1β, and LPS, leading to phosphorylation and degradation of IκBα, thereby releasing NF-κB dimers for nuclear translocation and target gene activation. Beyond its role in immune defense and inflammation, dysregulation of IKKβ signaling—through constitutive activation or overexpression—is closely associated with chronic inflammatory diseases (e.g., rheumatoid arthritis, inflammatory bowel disease), metabolic disorders, and multiple cancers (including hepatocellular carcinoma, colorectal cancer, and lymphoma), making it a highly validated target for anti-inflammatory therapy and cancer drug discovery.
Screeningbio’s IKKβ Kinase Assay Kit provides a robust, sensitive, and high-throughput platform for quantifying IKKβ kinase activity and evaluating the potency of tyrosine kinase inhibitors (TKIs).
This kit utilizes the ADP-Glo Kinase Assay platform, a luminescent technology that measures the amount of ADP produced during the kinase reaction.
The assay is performed in two distinct steps:
Kinase Reaction: IKKβ catalyzes the transfer of a phosphate group from ATP to a specific substrate, resulting in the production of phosphorylated substrate and ADP.
ADP-Glo™ Reagent Addition: After the kinase reaction, the ADP-Glo™ Reagent is added to terminate the reaction and deplete any remaining unreacted ATP.
Kinase Detection: The Kinase Detection Reagent is added to simultaneously convert the produced ADP back into ATP, which is then used by luciferase to generate a luminescent signal.
The light intensity produced is directly proportional to the ADP concentration and, consequently, to the enzymatic activity of the IKKβ kinase.
Data